Saturday, October 3, 2026

USD/EUR Rises By 1% In The Last 21 Sessions

USD/EUR Rises By 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.54% for the last 21 sessions. At 03:06 EST on Thursday, 2 March, USD/EUR (USDEUR) is $0.94.

USD/EUR's yearly highs and lows, it's 5.178% up from its 52-week low and 10.275% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was 0.26%, 0.23%, and 0.43%, respectively.

USD/EUR's highest amplitude of average volatility was 0.26% (last week), 0.47% (last month), and 0.43% (last quarter), respectively.

News about

  • Eur/usd to climb back towards 1.10 by the end of March – socgen. According to FXStreet on Tuesday, 28 February, "We argued that a bit of risk aversion and wider credit spreads could take EUR/USD to 1.06 (and GBP/USD below 1.2). ", "Both went marginally further, and we could still see some wobbles in the days ahead but yield differentials should start to matter again and I expect we'll be climbing back towards EUR/USD 1.10 by the end of March."
  • Eur/usd: inflation data might support the euro this week – commerzbank. According to FXStreet on Tuesday, 28 February, "For the time being, however, the USD side should be able to stand its ground so that scope for higher EUR/USD levels should be limited at present."
  • Eur/usd remains firm and climbs to 3-day highs near 1.0620. According to FXStreet on Tuesday, 28 February, "The single currency extends the auspicious start of the week and lifts EUR/USD to the 1.0620 region, or 3-session tops, on turnaround Tuesday.", "Price action around EUR/USD remains somewhat flat in line with the rest of the global markets, although the pair manages well to reclaim the area beyond 1.0600 the figure so far on Tuesday."
  • According to FXStreet on Tuesday, 28 February, "The Euro remains little impressed by the above comments, as EUR/USD loses 0.19% on the day to trade at 1.0585 at the time of writing."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com